Rare
lephants
Screener
Toggle theme
Kiniksa Pharmaceuticals International, plc
KNSA
·
Healthcare, Drug Manufacturers - General
Financial Statements
Profitability
Balance Sheet
Cash Flow
Price Ratios
Share-Based Metrics
Valuation
Cash Flow History
Net Cash Flow Breakdown
Net Cash Flow
Cash Flow
›
Net Cash Flow Breakdown
Net Cash Flow Breakdown
Chart
Table
FY2025
FY2024
FY2023
FY2022
Total Cash from Operations:
$213.4M
Line Item
Value
% of Total
Capital Expenditures
$105.0K
0.0%
Other Investing
$8.0M
3.7%
Working Capital
$205.1M
96.1%
Net Cash Flow
$245.0K
0.1%
Download CSV
